Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs

the ACTIVATE study

Håvard Midgard*, Behzad Hajarizadeh, Evan B. Cunningham, Brian Conway, Markus Backmund, Philip Bruggmann, Julie Bruneau, Stefan Bourgeois, Adrian Dunlop, Graham R. Foster, Margaret Hellard, Geert Robaeys, Maria C. Thurnheer, Martin Weltman, Janaki Amin, Philippa S. Marks, Sophie Quiene, Gregory J. Dore, Olav Dalgard, Jason Grebely & 1 others ACTIVATE Study Group

*Corresponding author for this work

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: The risk of hepatitis C virus (HCV) reinfection due to continued injecting risk behaviours might remain a barrier to HCV treatment among people who inject drugs. We aimed to evaluate changes in risk behaviours during and following HCV treatment among people with ongoing injecting drug use or receiving opioid substitution treatment (OST). Methods: ACTIVATE was an international multicentre clinical trial conducted between 2012 and 2014. Participants with HCV genotypes 2/3 infection were treated with peg-interferon/ribavirin for 12 or 24 weeks and completed a self-administered behavioural questionnaire at each study visit. The impact of time in treatment and follow-up on longitudinally measured recent (past month) behavioural outcomes was evaluated using generalized estimating equations. Results: Among 93 enrolled participants (83% male, median age 41 years), 55 (59%) had injected in the past month. Any injecting drug use decreased during HCV treatment and follow-up (OR 0.89 per incremental study visit; 95% CI 0.83-0.95). No significant changes were found in ≥daily injecting (OR 0.98; 95% CI 0.89-1.07), use of non-sterile needles (OR 0.94; 95% CI 0.79-1.12), sharing of injecting paraphernalia (OR 0.87; 95% CI 0.70-1.07) or non-injecting drug use (OR 1.01; 95% CI 0.92-1.10). Hazardous alcohol use decreased throughout (OR 0.56; 95% CI 0.40-0.77) and OST increased between enrolment and end of treatment (OR 1.48; 95% CI 1.07-2.04). Conclusions: Recent injecting drug use and hazardous alcohol use decreased, while OST increased during and following HCV treatment among participants with ongoing injecting drug use. These findings support further expansion of HCV care among PWID.

Original languageEnglish
Pages (from-to)230-238
Number of pages9
JournalInternational Journal of Drug Policy
Volume47
DOIs
Publication statusPublished - Sep 2017

    Fingerprint

Keywords

  • Alcohol use
  • Antiviral treatment
  • Hepatitis C virus
  • Injecting drug use
  • Opioid substitution treatment
  • People who inject drugs
  • Risk behaviours

Cite this